Not medical advice. FOXO4-DRI is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
FOXO4-DRI (Proxofim) is a senolytic peptide that selectively eliminates senescent "zombie" cells by disrupting the FOXO4-p53 interaction - one of the most-cited discoveries in modern aging research.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
FOXO4-DRI is a D-retro-inverso senolytic peptide that disrupts the FOXO4-p53 nuclear interaction to selectively induce apoptosis in senescent cells.
Peer-reviewed literature typically discusses FOXO4-DRI in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Researchers study these compounds for mitochondrial function, nutrient sensing, and cellular energy stress responses -often in ageing or metabolic disease models.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised: -20 °C long-term. 2–8 °C for active use. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 5–10 mg subcutaneous injection · 3 times weekly for 3–4 weeks per cycle, with 4–8 week rest periods · No formal human pharmacokinetic data published. D-retro-inverso configuration significantly extends in vivo stability versus L-peptide equivalents. In preclinical studies, FOXO4-DRI was dissolved in PBS at 5 mg/mL and administered intraperitoneally. The large molecular weight (5358.2 Da) limits oral bioavailability; parenteral administration required. Cleara Biotech is advancing clinical development of FOXO4-p53 interaction modulators.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
FOXO4-DRI (Proxofim) is studied as a senolytic tool compound - it is used in cell and animal models to selectively eliminate senescent cells by disrupting the FOXO4-p53 interaction. Researchers use it to probe how clearing "zombie" cells affects aged tissue, vascular function, and inflammation. It is supplied here for laboratory research only and is not for human use.
A senolytic is a compound that selectively kills senescent cells - cells that have stopped dividing but refuse to die and produce a damaging pro-inflammatory secretome. In animal studies, clearing senescent cells extends healthspan and improves tissue function. FOXO4-DRI is one of the best-characterised peptide senolytics, specifically targeting the FOXO4-p53 axis that keeps senescent cells alive.
D-retro-inverso topology (all D-amino acids in reverse order) preserves the side-chain orientation that a protein-protein interaction interface needs to see, while making the peptide resistant to proteases that normally chew up L-peptides. This is especially important for a senolytic, which needs to reach senescent cells in multiple tissues without being degraded in transit.
No. All published FOXO4-DRI data is preclinical - cell culture and animal models. The Baar et al. (Cell, 2017) mouse work is the foundational study, and a 2025 Nature Communications paper characterised how the peptide binds the disordered p53 transactivation domain. Clinical senolytic candidates based on the FOXO4-p53 mechanism are in development at Cleara Biotech, but FOXO4-DRI itself remains a research compound, not an approved therapy.
They are different senolytic strategies. Dasatinib + quercetin (D+Q) is a small-molecule combination that targets pro-survival pathways broadly across senescent cell types, while FOXO4-DRI is a peptide that specifically disrupts the FOXO4-p53 interaction. FOXO4-DRI is the more targeted, peptide-based approach; both are studied in aging research and neither is established as a human therapy.
Baar et al. (Cell, 2017) showed that FOXO4-DRI selectively kills senescent cells while sparing non-senescent dividing cells in vitro. The selectivity comes from the fact that senescent cells specifically rely on FOXO4 to sequester p53, whereas healthy cells do not have the same dependency. That said, senolytic selectivity is an active research area and appropriate caution is warranted.
Keep the lyophilised powder frozen at −20 °C for long-term storage, or at 2-8 °C during active research use. Reconstitute with sterile PBS or bacteriostatic water. The D-retro-inverso topology gives it unusually good stability in solution compared with L-peptides.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside FOXO4-DRI.
Primary literature and registries for FOXO4-DRI, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: FOXO4-DRI, Proxofim, FOXO4 D-Retro-Inverso Peptide, FOXO4-p53 Interaction Blocker, Senolytic Peptide FOXO4-DRI, ES2